Cite
MiR-17- 5p/RRM2 regulated gemcitabine resistance in lung cancer A549 cells.
MLA
Ma, Xuan, et al. “MiR-17- 5p/RRM2 Regulated Gemcitabine Resistance in Lung Cancer A549 Cells.” Cell Cycle (Georgetown, Tex.), vol. 22, no. 11, June 2023, pp. 1367–79. EBSCOhost, https://doi.org/10.1080/15384101.2023.2207247.
APA
Ma, X., Fu, T., Ke, Z.-Y., Du, S.-L., Wang, X.-C., Zhou, N., Zhong, M.-Y., Liu, Y.-J., & Liang, A.-L. (2023). MiR-17- 5p/RRM2 regulated gemcitabine resistance in lung cancer A549 cells. Cell Cycle (Georgetown, Tex.), 22(11), 1367–1379. https://doi.org/10.1080/15384101.2023.2207247
Chicago
Ma, Xuan, Tian Fu, Zhi-Yin Ke, Shen-Lin Du, Xue-Chun Wang, Ning Zhou, Mu-Yi Zhong, Yong-Jun Liu, and Ai-Ling Liang. 2023. “MiR-17- 5p/RRM2 Regulated Gemcitabine Resistance in Lung Cancer A549 Cells.” Cell Cycle (Georgetown, Tex.) 22 (11): 1367–79. doi:10.1080/15384101.2023.2207247.